Clinical Trials · NCT01144338
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 14,752
- Start date
- Jun 2010
- Locations
- 629 sites, 35 countries
- Primary endpoint
- Primary Efficacy Outcome MACE Events